PCV

PS

VAR

Pneumococcal conjugate vaccine

Primary series

Varicella vaccine

		4:3:1	:3:3:1		4:3:1:3:3:1:4				4:3:1:-:3:1:4				4:3:1:3 [‡] :3:1:4			
	U.S.	± CI	ldaho	± CI	U.S.	± CI	Idaho	± CI	U.S.	± CI	Idaho	± CI	U.S.	± CI	ldaho	± CI
2006, n=222	76.9	1.0	68.2	6.9												
2007, n=183	77.4	1.1	65.7	7.2	66.5	1.3	52.9	7.6								
2008, n=282	76.1	1.1	60.4	6.8	68.4	1.2	54.2	6.7	70.6	1.2	60.4	6.6				
2009, n=207	69.9	1.2	51.7	7.7	63.6	1.3	48.0	7.7	70.5	1.2	70.5	7.0	44.3	1.4	33.6	7.2
2010, n=271	74.9	1.1	61.2	6.7	70.2	1.3	57.4	6.8	72.7	1.2	66.3	6.4	56.6	1.3	42.6	6.8
2011, n=317	77.0	1.1	68.8	7.6	73.3	1.2	66.9	7.7	73.6	1.2	66.9	7.7	68.5	1.3	57.1	8.4
2012, n=289	71.9	1.4	64.5	8.1									68.4	1.4	63.0	8.2
2013, n=233	74.0	1.4	71.6	6.8					72.7	1.5	76.2	6.4	70.4	1.5	70.2	6.9
2014, n=235	74.6	1.4	67.2	8.0									71.6	1.5	65.9	8.0
2015, n=209	75.1	1.3	73.7	6.6					UNK	UNK	UNK	UNK	72.2	1.4	71.6	6.8

		4+ DTaP	/DTP/DT			3+ Polic	vaccine		1+ MMR				
	U.S.	± CI	ldaho	± CI	U.S.	± CI	Idaho	± CI	U.S.	± CI	Idaho	± CI	
2006, n=222	85.2	0.9	82.4	5.8	92.8	0.6	92.2	3.9	92.3	0.6	88.0	4.8	
2007, n=183	84.5	0.9	77.2	6.3	92.6	0.7	87.6	4.9	92.3	0.7	86.1	5.2	
2008, n=282	84.6	1.0	77.6	5.9	93.6	0.6	91.8	3.7	92.1	0.7	86.1	5.4	
2009, n=207	83.9	1.0	84.0	5.5	92.8	0.7	94.7	3.5	90.0	0.8	88.1	4.8	
2010, n=271	84.4	1.0	77.9	5.7	93.3	0.7	89.2	4.7	91.5	0.7	87.2	5.0	
2011, n=317	84.6	1.0	79.0	6.6	93.9	0.6	94.5	3.1	91.6	0.8	89.5	4.8	
2012, n=289	82.5	1.2	76.6	6.7	92.8	0.7	92.6	3.9	90.8	0.8	93.3	3.6	
2013, n=233	83.1	1.3	84.2	5.3	92.7	1.0	92.6	3.7	91.9	0.9	91.1	4.3	
2014, n=235	84.2	1.2	77.7	7.2	93.3	0.8	93.1	4.3	91.5	0.9	89.7	5.1	
2015, n=209	84.6	1.1	81.0	5.9	93.7	0.6	88.9	4.9	91.9	0.8	91.2	4.0	

		HIE	3-FS			3+ HIB	vaccine		HIB-PS				
	U.S.	± CI	Idaho	± CI	U.S.	± CI	Idaho	± CI	U.S.	± CI	Idaho	± CI	
2006, n=222					93.4	0.6	91.3	4.2					
2007, n=183					92.6	0.7	86.3	5.1					
2008, n=282					90.9	0.7	77.6	3.4					
2009, n=207					86.6	1.0	64.1	7.5	92.1	0.8	90.9	4.5	
2010, n=271	66.8	1.3	53.3	6.9	90.4	0.9	77.7	6.2	92.2	0.8	82.3	5.9	
2011, n=317	80.4	1.1	75.0	7.3	94.0	0.6	94.7	3.1	94.2	0.6	94.9	3.1	
2012, n=289	80.9	1.2	77.3	7.6					93.3	0.7	92.7	3.9	
2013, n=233	82.0	1.3	80.0	5.9	92.3	0.9	91.2	4.3	93.3	0.9	94.7	3.1	
2014, n=235	82.0	1.3	80.4	6.5	91.9	0.9	92.3	4.4	92.8	0.9	94.9	3.6	
2015, n=209	82.7	1.1	81.2	5.9	92.4	0.7	88.3	4.9	93.7	0.7	90.3	4.4	


		1+1	VAR			4+ [PCV		2+ Hep A vaccine				
	U.S.	± CI	ldaho	± CI	U.S.	± CI	Idaho	± CI	U.S.	± CI	Idaho	± CI	
2006, n=222	89.2	0.7	77.4	6.1	68.4	1.1	72.1	6.5					
2007, n=183	90.0	0.7	75.5	6.4	75.3	1.2	66.6	7.2					
2008, n=282	90.7	0.7	80.7	5.8	80.1	1.1	74.8	6.3	40.4	1.2	38.6	6.5	
2009, n=207	89.6	0.8	84.1	5.7	80.4	1.1	82.5	6.0	46.6	1.4	37.3	7.5	
2010, n=271	90.4	0.8	83.7	5.1	83.3	1.0	79.7	5.5	49.7	1.4	44.2	6.8	
2011, n=317	90.8	0.7	86.0	5.6	84.4	1.0	84.1	5.7	52.2	1.4	45.2	8.6	
2012, n=289	90.2	0.1	90.3	4.3	81.9	1.1	83.9	4.8	53.0	1.1	52.8	8.6	
2013, n=233	91.2	0.9	87.9	4.8	82.0	1.3	87.3	4.6	54.7	1.6	60.7	7.3	
2014, n=235	91.0	0.9	90.0	5.0	82.9	1.3	83.6	6.2	57.5	1.6	59.4	8.2	
2015, n=209	91.8	0.8	88.5	4.6	84.1	1.1	84.4	5.5	59.6	1.5	58.8	7.3	

		Rota	virus		H	ep B vaccir	ne birth do	se	3+ Hep B vaccine				
	U.S.	± CI	Idaho	± CI	U.S.	± CI	Idaho	± CI	U.S.	± CI	Idaho	± CI	
2006, n=222									93.3	0.6	92.9	3.5	
2007, n=183									92.7	0.7	88.8	4.7	
2008, n=282					55.3	1.3	64.0	6.6	93.5	0.7	93.3	3.4	
2009, n=207	43.9	1.4	30.3	7.2	60.8	1.3	70.3	7.1	92.4	0.7	94.3	3.6	
2010, n=271	59.2	1.4	50.4	6.9	64.1	1.3	65.2	6.4	91.8	0.7	86.8	4.9	
2011, n=317	67.3	1.3	62.0	8.2	68.6	1.3	70.2	7.5	91.1	0.7	86.3	5.4	
2012, n=289	68.6	1.4	68.2	7.2	71.6	1.4	70.1	7.8	89.0	0.9	87.7	5.0	
2013, n=233	72.6	1.5	74.6	6.4	74.2	1.4	72.7	6.5	90.8	1.0	90.7	4.3	
2014, n=235	71.7	1.6	79.5	6.7	72.4	1.5	75.4	7.4	91.6	0.9	95.1	3.5	
2015, n=209	73.2	1.4	74.5	6.6	73.3	1.4	71.1	7.5	92.6	0.7	89.8	4.6	

¹ Full series *Haemophilus influenzae* type b (Hib) vaccine: ≥3 or ≥4 doses, depending on brand received Idaho data points in BOLD indicate a statistically significant change compared with the previous year, p=0.05 Blue cells indicate NIS did not collect data during that year CI = Confidence Interval UNK=Unknown

Glossary of Abbreviations and Terms

4:3:1:3:3:1	The series of 4 or more DTaP vaccinations, 3 or more polio vaccinations, 1 or more MMR vaccinations, 3 or more Hib vaccinations of any type, 3 or more hepatitis B vaccinations, and 1 or more varicella vaccinations given at age 12 months or older
4:3:1:3 [‡] :3:1:3	The series of 4 or more DTaP vaccinations, 3 or more polio vaccinations, 1 or more MMR vaccinations, 2 or 3 Hib vaccinations depending on brand received, 3 or more hepatitis B vaccinations, 1 or more varicella vaccinations given at age 12 months or older, and 4 or more pneumococcal vaccinations
4:3:1:3:3:1:4	The series of 4 or more DTaP vaccinations, 3 or more polio vaccinations, 1 or more MMR vaccinations, 3 or more Hib vaccinations of any type, 3 or more hepatitis B vaccinations, 1 or more varicella vaccinations given at age 12 months or older, and 4 or more pneumococcal vaccinations
4:3:1:-:3:1:4	The series of 4 or more DTaP vaccinations, 3 or more polio vaccinations, 1 or more MMR vaccinations, 3 or more hepatitis B vaccinations, 1 or more varicella vaccinations given at age 12 months or older, and 4 or more pneumococcal vaccinations
DTaP	Diphtheria and tetanus toxoids and acellular pertussis vaccine
DTP	Diphtheria and tetanus toxoids and pertussis vaccine
DT	Diphtheria and tetanus toxoids vaccine
FS	Full series
Нер А	Hepatitis A
Нер В	Hepatitis B
Hib	Haemophilus influenzae type b
MMR	Measles, mumps, and rubella vaccine
NIS	National Immunization Survey




^{*} Refers to 4 or more doses of diphtheria and tetanus toxoids and pertussis vaccine, or diphtheria and tetanus toxoids (DTP/DT/DTaP), 3 or more doses of polio virus vaccine, 1 or more doses a measles-mumps-rubella (MMR) vaccine, 3 or more doses of *Haemophilus influenzae* type b (Hib) vaccine of any type, 3 or more doses of hepatitis B vaccine, and 1 or more doses of varicella vaccine

⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

^{*}Refers to a statistically significant change compared to the previous year, p=0.05

n = number of children sampled for each survey year in Idaho




^{*} Refers to 4 or more doses of diphtheria and tetanus toxoids and pertussis vaccine, or diphtheria and tetanus toxoids (DTP/DT/DTaP), 3 or more doses of polio virus vaccine, 1 or more doses of measles-mumps-rubella vaccine (MMR), 3 or more doses of *Haemophilus influenzae* type b (Hib) vaccine of any type, 3 or more doses of hepatitis B vaccine, 1 or more doses of varicella vaccine, and 4 or more doses of pneumococcal conjugate vaccine (PCV)

⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

[§] This series was sampled during 2007 through 2011

n = number of children sampled for each survey year in Idaho



^{*}Refers to 4 or more doses of diphtheria and tetanus toxoids and pertussis vaccine, or diphtheria and tetanus toxoids (DTP/DT/DTaP), 3 or more doses of polio virus vaccine, 1 or more doses of measles-mumps-rubella vaccine (MMR), Haemophilus influenzae type b (Hib) vaccine is excluded, 3 or more doses of hepatitis B vaccine, 1 or more doses of varicella vaccine, and 4 or more doses of pneumococcal conjugate vaccine (PCV)


UNK=Unknown

⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

[§] This series was sampled during 2008 through 2011 to exclude the impact of the national Hib vaccine shortage and not sampled during 2012 and 2014

^{*}Refers to a statistically significant change compared to the previous year, p=0.05

n = number of children sampled for each survey year in Idaho




*Refers to 4 or more doses of diphtheria and tetanus toxoids and pertussis vaccine, or diphtheria and tetanus toxoids (DTP/DT/DTaP), 3 or more doses of polio virus vaccine, 1 or more doses of a measles-mumps-rubella vaccine (MMR), plus full series of *Haemophilus influenzae* type b (Hib), 3 or more doses of hepatitis B vaccine, 1 or more doses of varicella vaccine, and 4 or more doses of pneumococcal conjugate vaccine (PCV)

[‡] Full series Haemophilus influenzae type b (Hib) vaccine: ≥3 or ≥4 doses, depending on brand received

⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

[§] This series sampling began in 2012, however in 2013 data was published for 2009–2011 rates


n = number of children sampled for each survey year in Idaho



^{*}Refers to 4 or more doses of diphtheria and tetanus toxoids and pertussis vaccine, or diphtheria and tetanus toxoids (DTP/DT/DTaP)


⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

n = number of children sampled for each survey year in Idaho




^{*} Refers to 3 or more doses of any polio virus vaccine

⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months n = number of children sampled for each survey year in Idaho



⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

n = number of children sampled for each survey year in Idaho




^{*} Refers to full series Haemophilus influenzae type b (Hib) vaccine: ≥3 or ≥4 doses, depending on brand received

⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

[§] This series sampling began in 2010

n = number of children sampled for each survey year in Idaho




^{*} Refers to 3 or more doses of *Haemophilus influenzae* type b (Hib) vaccine

n = number of children sampled for each survey year in Idaho

⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

[§] This series was sampled during 2006 through 2014 except 2012

 $^{^{\}mbox{\scriptsize 4}}$ Refers to a statistically significant change compared to the previous year, p=0.05




^{*} Refers to primary series Haemophilus influenzae type b (Hib) vaccine: ≥2 or ≥3 doses, depending on brand received

⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

[§] This series sampling began in 2009

[¥] Refers to a statistically significant change compared to the previous year, p=0.05


n = number of children sampled for each survey year in Idaho




^{*} Refers to 1 or more doses of varicella vaccine at or after child's first birthday, unadjusted for history of varicella illness

⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

n = number of children sampled for each survey year in Idaho






^{*} Refers to 2 or more doses of hepatitis A vaccine

⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

[§] This series sampling began in 2008

n = number of children sampled for each survey year in Idaho




^{*} Refers to ≥2 or ≥3 doses of rotavirus vaccine depending on brand received

n = number of children sampled for each survey year in Idaho

⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

[§] This series sampling began in 2009

^{*} Refers to a statistically significant change compared to the previous year, p=0.05




^{*}Refers to 1 or more doses of hepatitis B vaccine administered between birth and age 3 days

⁺From the National Immunization Survey (NIS), children aged 19 through 35 months

[§] This series sampling began in 2008

n = number of children sampled for each survey year in Idaho



^{*} Refers to 3 or more doses of hepatitis B vaccine

⁺ From the National Immunization Survey (NIS), children aged 19 through 35 months

^{*} Refers to a statistically significant change compared to the previous year, p=0.05

n = number of children sampled for each survey year in Idaho